Trial · NCT03284957
Adverse events3,904
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,904
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | Part A: Amcenestrant 20 mg | 0 | 3 | 0 |
| other | Bronchitis | Infections and infestations | Part A: Amcenestrant 150 mg | 0 | 3 | 0 |
| other | Bronchitis | Infections and infestations | Part A: Amcenestrant 200 mg | 0 | 4 | 0 |
| other | Bronchitis | Infections and infestations | Part A: Amcenestrant 400 mg | 0 | 3 | 0 |
| other | Bronchitis | Infections and infestations | Part A: Amcenestrant 600 mg | 0 | 3 | 0 |
| other | Bronchitis | Infections and infestations | Part A: Amcenestrant 300 mg BID | 0 | 6 | 0 |
| other | Bronchitis | Infections and infestations | Part B: Amcenestrant 400 mg | 0 | 49 | 0 |
| other | Bronchitis | Infections and infestations | Part C: Amcenestrant 200 mg + Palbociclib 125 mg | 0 | 9 | 0 |
| other | Bronchitis | Infections and infestations | Part C: Amcenestrant 400 mg + Palbociclib 125 mg | 0 | 6 | 0 |
| other | Bronchitis | Infections and infestations | Part D: Amcenestrant 200 mg + Palbociclib 125 mg | 0 | 30 | 0 |
| other | Bronchitis | Infections and infestations | Part F: Amcenestrant 200 mg + Alpelisib 300 mg | 1 | 8 | 2 |
| other | Bronchitis | Infections and infestations | Part H: Amcenestrant 200 mg + Everolimus 5 mg | 1 | 3 | 1 |
| other | Bronchitis | Infections and infestations | Part H: Amcenestrant 200 mg + Everolimus 10 mg | 0 | 3 | 0 |
| other | Bronchitis | Infections and infestations | Part I: Amcenestrant 200 mg + Everolimus 10 mg | 0 | 1 | 0 |
| other | Bronchitis | Infections and infestations | Part J: Amcenestrant 200 mg + Abemaciclib 100 mg BID | 0 | 3 | 0 |
| other | Bronchitis | Infections and infestations | Part J: Amcenestrant 200 mg + Abemaciclib 150 mg BID | 0 | 2 | 0 |
| other | Covid-19 | Infections and infestations | Part A: Amcenestrant 20 mg | 0 | 3 | 0 |
| other | Covid-19 | Infections and infestations | Part A: Amcenestrant 150 mg | 0 | 3 | 0 |
| other | Covid-19 | Infections and infestations | Part A: Amcenestrant 200 mg | 0 | 4 | 0 |
| other | Covid-19 | Infections and infestations | Part A: Amcenestrant 400 mg | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03284957/events